{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:48:20Z","timestamp":1774846100743,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgo.2020.09.015","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T03:03:16Z","timestamp":1600743796000},"page":"320-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective"],"prefix":"10.1016","volume":"12","author":[{"given":"Vicki A.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2020.09.015_bb0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2020.09.015_bb0010","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"German high-grade non-Hodgkin lymphoma study group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0020","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood.V116.21.589.589","article-title":"R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients: Long-term follow-up of intergroup E4494\/C9793","volume":"116","author":"Morrison","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.09.015_bb0025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"1","author":"Coiffier","year":"2016","journal-title":"Hematology"},{"issue":"20","key":"10.1016\/j.jgo.2020.09.015_bb0030","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2020.09.015_bb0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.09.015_bb0040","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.14694\/EdBook_AM.2015.35.e458","article-title":"Cell-of-origin in diffuse large B-cell lymphoma: are the assays ready for the clinic?","author":"Scott","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"20","key":"10.1016\/j.jgo.2020.09.015_bb0045","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jgo.2020.09.015_bb0050","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0055","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard C+CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"Recher","year":"2011","journal-title":"Lancet"},{"issue":"35","key":"10.1016\/j.jgo.2020.09.015_bb0060","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.2013.54.9493","volume":"32","author":"Molina","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0065","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A Cancer and Leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2020.09.015_bb0070","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0075","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0080","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2020.09.015_bb0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0090","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose adjusted-EPOCH-R compared to R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase 3 intergroup trial CALGB 50303 (Alliance)","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0095","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2020.09.015_bb0105","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1080\/10428194.2018.1515940","article-title":"Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study","volume":"60","author":"Sharman","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2020.09.015_bb0110","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0115","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination halflife in elderly patients with DLBCL","volume":"119","author":"Muller","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.09.015_bb0120","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.09.015_bb0125","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14860","article-title":"Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients","volume":"179","author":"Pfreundschuh","year":"2017","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jgo.2020.09.015_bb0130","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2013.100818","article-title":"R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes","volume":"99","author":"Seymour","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2020.09.015_bb0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2020.09.015_bb0140","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0145","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multi-Centre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2020.09.015_bb0150","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/10428194.2015.1045898","article-title":"A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma","volume":"57","author":"Hainsworth","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2020.09.015_bb0155","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","article-title":"Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial","volume":"3","author":"Johnston","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0160","article-title":"High rate of event-free survival at 24 months with everolimus\/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)","volume":"7","author":"Witzig","year":"2017","journal-title":"Blood Ca J"},{"key":"10.1016\/j.jgo.2020.09.015_bb0165","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell\u2013like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0170","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00277-018-3435-1","article-title":"The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis","volume":"97","author":"Lin","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0175","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin,vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jgo.2020.09.015_bb0180","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2019.37.15_suppl.7520","article-title":"Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL","volume":"37","author":"Nowakowski","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jgo.2020.09.015_bb0185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V114.22.408.408","article-title":"R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines","volume":"114","author":"Moccia","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.09.015_bb0190","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3109\/10428194.2015.1096356","article-title":"Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria","volume":"57","author":"Rashidi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2020.09.015_bb0195","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3109\/10428194.2014.982645","article-title":"Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma","volume":"56","author":"Gang","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2020.09.015_bb0200","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","article-title":"Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial","volume":"5","author":"Shen","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0210","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13652","article-title":"Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicenter randomized phase III trial","volume":"171","author":"Witzens-Harig","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0215","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0220","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2016.255","article-title":"A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high\/high-intermediate risk diffuse large B-cell lymphoma","volume":"31","author":"Reddy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2020.09.015_bb0225","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma","volume":"34","author":"Crump","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0230","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdx764","article-title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial","volume":"29","author":"Witzig","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0235","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.09.015_bb0240","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Mamot","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2020.09.015_bb0245","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/bloodadvances.2019001201","article-title":"SAKK38\/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model","volume":"4","author":"Ceriani","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.jgo.2020.09.015_bb0250","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jgo.2020.09.015_bb0255","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood.2019003277","article-title":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial","volume":"135","author":"Schoder","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.09.015_bb0260","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxy- daunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820304422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820304422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:54:09Z","timestamp":1761818049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406820304422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1879406820304422"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.09.015","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}